Allergy Therapeutics Reports Positive Progress in Phase 2a Trial of VLP Peanut Allergy Vaccine
核心洞察
Allergy Therapeutics (搜索)' VLP Peanut vaccine candidate demonstrated positive progress in Phase 1 and Phase 2a trials, showing reduction in allergic response to major peanut allergens.
Interim analysis from the PROTECT trial's first two cohorts revealed no relevant safety signals across healthy and peanut-allergic adult subjects.
The company plans to advance VLP Peanut into Phase 2b development, positioning it as the most advanced peanut vaccine program in the industry.
Allergy Therapeutics (搜索) PLC announced positive interim results from its PROTECT trial evaluating VLP Peanut, a short-course vaccine candidate for peanut allergy. The Sussex, England-based biotechnology company reported that the vaccine demonstrated encouraging efficacy signals and maintained a favorable safety profile across Phase 1 and Phase 2a testing.
Trial Progress and Safety Profile
The PROTECT trial's interim analysis from the first two cohorts of peanut allergic patients indicated that VLP Peanut is driving a reduction in allergic response to the major peanut allergen. The company reported that no relevant safety signals were identified across each of the trial's cohorts, which included both healthy and peanut-allergic adult subjects.
The final stage of the PROTECT trial is progressing as planned, with one final cohort of peanut allergic patients remaining. Dosing for this cohort is expected to extend beyond the candidate's anticipated therapeutic range.
Clinical Significance and Market Position
Chief Executive Officer Manuel Llobet emphasized the significance of these results for the allergy research community. "These results signal a major advance in the allergy research community's search for what remains our holy grail - an effective short-course vaccine for people living with peanut allergy," Llobet stated.
The CEO highlighted that the vaccine candidate's positive safety profile, combined with encouraging early efficacy signals showing a strong immune response and reduced allergic reactivity, strengthens confidence in the program's potential to transform lives of those affected by peanut allergy.
Development Timeline and Industry Leadership
Allergy Therapeutics (搜索) plans to progress VLP Peanut into Phase 2b development, with Llobet positioning the program as "the most advanced peanut vaccine programme in the industry." The company aims to continue leading innovation in allergy treatment through this development pathway.
The positive trial results were well-received by investors, with shares in Allergy Therapeutics (搜索) rising 3.8% in London trading, closing at 8.30 pence on Thursday following the announcement.